Gastroprotective flavone/flavanone compounds with therapeutic ef

Details Gastroprotective flavone/flavanone compounds with therapeutic ef Gastroprotective flavone/flavanone compounds with therapeutic ef

1999-01-14

2000-02-15

Richter, Johann

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

549288, 549289, A61K 31365, C07D31130, C07D31132

Patent

active

060253878

DESCRIPTION:

BRIEF SUMMARY
FIELD OF THE INVENTION

The present invention relates to novel flavone/flavanone compounds or their pharmaceutically acceptable salts, and process for preparation thereof for protecting gastrointestinal tracts against gastritis, ulcers and inflammatory bowel disease.


BACKGROUND OF THE INVENTION

Although the incidence of gastric ulceration, duodenal ulceration or gastritis has been declining over the last decade, about 10% of the population will develop this condition at some time during their lives. The precise cause of these diseases remains uncertain despite of intensive clinical and laboratory research, but it is explained that they are induced from imbalance in equlibrium between potentially damaging factor present in the lumen of the stomach or duodenum and the process which enable these tissues to resist autodigestion.
The first line therapy for gastritis and gastric ulcer is to promote the effects of treatments by attenuating the attacking factors by administering antisecretory agents such as antacid, H2 antagonists and proton pump inhibitors. However, it has been reported that in the cases of omeprazole or long acting H2 antagonists, the duration of action was so long more than 24 hours that their long-term administration to rats caused dysplasia in epidermal cells of mucous membrane in gastrointestinal tracts (Ekman, L. et al., Scand. J. Gastroentrol.1985, 20 suppl.108: 53). And long-term administration of antisecretory agents is frequently associated with formation of gastric tumors in animals (Garner, A., Advances in Drug Therapy of Gastrointestinal Ulceration; Garner, A. and Whittle, B. J. R.(Eds.), Wiley & Sons, 1989, 275-88). Furthermore, a majority of patients with peptic ulcer disease have acid outputs within the normal range (Baron, J. H., Clinical Tests of Gastric Secretion. Macmillan, London, 1978, 86-119), so the treatments with antisecretory agents are not fundamental therapy and have a little effect on the prevention of recurrence, though they enhance acute healing of ulcer.
On the contrary cytoprotective agents such as sucralfate showed low frequency of recurrence (Marks, I. N., et al., Scand. J. Gastroentrol. 1983, 18 Suppl.83: 53. Shorrock, C. J., et al., Gut 1990, 31: 26), which implies that stimulating of mucosal defence is more desirable than attenuating the attacking factors for treatment of these diseases.
The anti-ulcer action without antisecretory activity is referred to as `cytoprotection`. This cytoprotection is known to be due to the function of prostaglandins released from the gastric mucous membrane (Robert, A., 1981. Gastroenterology,16 Suppl.67: 223). Various kinds of prostaglandins such as PEI.sub.2, PGE.sub.2 are mainly generated in the gastric mucosa, and they effectively prevent the experimental ulceration induced by various kinds of ulcerogens (Robert. A., 1976. Advances in Prostaglandin and Thromboxane Research, Raven Press, New York, Vol 2, p.507). It was clinically proved that misoprostol, one of the prostaglandin compounds, prevented the gastric ulcer induced by NSAIDs (Graham, D. Y., et al., Lancet 1988, 2: 1277; Edelson, J. T., et al., JAMA 1990, 264: 41).
The cytoprotective mechanism of prostaglandins includes stimulating the blood flow of gastric mucosa (Guth, P. H., et al., Gastroenterology, 1984, 87: 1083), promoting mucus secretion (Allen, A., et al., Gut 1980, 21: 249; Rees, W. D. W., et al., Clin. Sci. 1982, 62: 343), promoting the gastric alkali secretion (Dayton, M. T., et al., Dig. Dis. Sci. 1983, 28; 449; Miller, T. A., et al., ibid 1983, 28; 641), preventing against the destruction of the gastric mucous defenses (Cheung, L. Y., Prostaglandins 1981, 21: 125), promoting the active transportation of sodium (Chaudhury, T. K., et al., Dig. Dis. Sci. 1980, 25: 830), stabilizing the lysozymes (Ferguson, W. W., et al., Am. Surg. 1973, 177: 648), and so on.
It has been also suggested that the tissue damages of many organs are induced by reactive oxygen species, such as lipid peroxides (Fridrich J., Science, 1978, 201: 875; Halliwell B, et al., Lancet

REFERENCES:
patent: 5399584 (1995-03-01), Ares et al.
Ares et al., J. Med. Chem., vol. 38, p. 4937-4943, 1995.
Gutierrez et al. Phytochemistry, vol. 39(4), p. 795-800, 1995.

Affiliated with

Also associated with

Rating

Gastroprotective flavone/flavanone compounds with therapeutic ef does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Gastroprotective flavone/flavanone compounds with therapeutic ef, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gastroprotective flavone/flavanone compounds with therapeutic ef will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1906406